Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP

Gudbjorg Edda Eggertsdottir, President Iceland & EVP Strategic Projects Actavis Group (Switzerland), the world’s third-largest generic maker, is eyeing three monoclonal antibodies for its entry into the Japanese biosimilar market, Gudbjorg Edda Eggertsdottir, President Iceland & EVP Strategic Projects, revealed...read more